- Home
- DERM vs CLLS Comparison
DERM vs CLLS Comparison
Compare DERM & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- CLLS
- Stock Information
- Founded
- DERM 2014
- CLLS 1999
- Country
- DERM United States
- CLLS France
- Employees
- DERM N/A
- CLLS N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- CLLS Health Care
- Exchange
- DERM Nasdaq
- CLLS Nasdaq
- Market Cap
- DERM 140.0M
- CLLS 148.1M
- IPO Year
- DERM 2021
- CLLS 2007
- Fundamental
- Price
- DERM $6.25
- CLLS $1.45
- Analyst Decision
- DERM Strong Buy
- CLLS Buy
- Analyst Count
- DERM 2
- CLLS 3
- Target Price
- DERM $10.00
- CLLS $7.00
- AVG Volume (30 Days)
- DERM 103.6K
- CLLS 120.5K
- Earning Date
- DERM 05-12-2025
- CLLS 05-27-2025
- Dividend Yield
- DERM N/A
- CLLS N/A
- EPS Growth
- DERM N/A
- CLLS N/A
- EPS
- DERM N/A
- CLLS N/A
- Revenue
- DERM $56,134,000.00
- CLLS $49,217,000.00
- Revenue This Year
- DERM $29.83
- CLLS $1.26
- Revenue Next Year
- DERM $54.88
- CLLS N/A
- P/E Ratio
- DERM N/A
- CLLS N/A
- Revenue Growth
- DERM N/A
- CLLS 435.38
- 52 Week Low
- DERM $3.20
- CLLS $1.10
- 52 Week High
- DERM $7.29
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- DERM 53.65
- CLLS 60.38
- Support Level
- DERM $5.98
- CLLS $1.40
- Resistance Level
- DERM $6.40
- CLLS $1.56
- Average True Range (ATR)
- DERM 0.62
- CLLS 0.09
- MACD
- DERM -0.06
- CLLS 0.03
- Stochastic Oscillator
- DERM 36.97
- CLLS 76.09
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.